AstraZeneca Says Prilosec OTC Sales “Flattish” In The First Quarter
This article was originally published in The Tan Sheet
Executive Summary
Sales of Procter & Gamble's Prilosec OTC leveled off in the first quarter compared to the three months of its initial launch last year, according to AstraZeneca
You may also be interested in...
P&G Builds Heartburn Market Lead, Continues Focus On Whitening Products
Prilosec OTC's sustained momentum helped produce a 17% gain in unit volume for Procter & Gamble's health care segment in the second quarter (ended Dec. 31). Sales for the unit rose 22% to $1.91 bil. and earnings advanced 32% to $333 mil
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands